Compare HP Inc (HPQ) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HP Inc vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? HP Inc trades at $30.42 (market cap $27.47B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M). The key difference: HP Inc is far larger — about 28.1× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and HP Inc pays a 3.94% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold HP Inc for 70 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| HPQ | MRVI | |
|---|---|---|
Market Cap | $27.47B | $977.37M |
Volume | 11,226,290 | 2,742,564 |
Sector | Technology | Health |
52-Week High | $35.48 | $9.00 |
52-Week Low | $18.20 | $2.83 |
Typical Hold Time | 70 Days | 0 Days |
Enterprise Value | $33.64B | $1.08B |
Dividend Yield | 3.94% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HPQ trades at $30.63, up 2.54% today, with a bearish technical signal but strong earnings beats in recent quarters. The company reported $55.3B revenue in 2025 with a net income margin of 4.14%, supported by a low P/E of 11.69. Recent news highlights product launches and AI integration in PCs, though the stock faces headwinds from a forecasted PC market decline in 2027.
The outlook is mixed: valuation metrics appear attractive, and dividend sustainability is supported by cash flow, but risks from PC market softness and negative shareholder equity warrant caution. Analyst consensus is neutral with a $25.75 price target, suggesting limited upside from current levels amid industry challenges.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About HP Inc
HP Incorporated is a leading provider of computers, printers, and printer supplies. The company's mains segments are personal systems and printing. Its personal systems segment contains notebooks, desktops, and workstations. Its printing segment contains supplies, consumer hardware, and commercial hardware. In 2015, Hewlett-Packard was separated into HP Incorporated and Hewlett Packard Enterprise and the Palo Alto, California-based HP Incorporated sells on a global scale.
Read more on HPQ →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
